Vertex Pharmaceuticals Director Sells $479,284 in Stock (VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX) Director Joshua S. Boger sold 5,200 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $92.17, for a total transaction of $479,284.00. Following the completion of the sale, the director now directly owns 338,895 shares of the company’s stock, valued at approximately $31,235,952. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 1.55% on Friday, hitting $87.53. The stock had a trading volume of 2,479,512 shares. Vertex Pharmaceuticals has a 52 week low of $58.06 and a 52 week high of $99.74. The stock has a 50-day moving average of $89.28 and a 200-day moving average of $77.98. The company’s market cap is $20.773 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings data on Tuesday, July 29th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.71) by $0.10. The company had revenue of $138.42 million for the quarter, compared to the consensus estimate of $131.85 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. The company’s quarterly revenue was down 55.5% on a year-over-year basis. Analysts expect that Vertex Pharmaceuticals will post $-2.85 EPS for the current fiscal year.
A number of research firms have recently commented on VRTX. Analysts at Zacks reiterated a “neutral” rating on shares of Vertex Pharmaceuticals in a research note on Thursday. They now have a $97.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 9th. Eight equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Vertex Pharmaceuticals presently has an average rating of “Hold” and an average price target of $102.82.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.